Sommario
L’ipoparatiroidismo è l’unico deficit endocrino nel quale la terapia sostitutiva con l’ormone mancante, il paratormone (PTH), non è ancora in uso comune. La terapia convenzionale spesso non consente un soddisfacente controllo clinico e non previene la comparsa delle complicanze croniche. Il PTH 1-34 e PTH 1-84 hanno dimostrato di ridurre il fabbisogno di calcio e metaboliti attivi della vitamina D, di normalizzare le alterazioni del metabolismo osseo legate al deficit di PTH e di migliorare la qualità della vita dei pazienti.
This is a preview of subscription content, log in via an institution to check access.
Bibliografia
Bollerslev J, Rejnmark L, Marcocci C et al. (2015) European society of endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 173(2):G1–G20
Cusano NE, Rubin MR, Irani D et al. (2013) Use of parathyroid hormone in hypoparathyroidism. J Endocrinol Invest 36(11):1121–1127
Winer KK, Ko CW, Reynolds JC et al. (2003) Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 88(9):4214–4220
Winer KK, Sinaii N, Reynolds J et al. (2010) Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab 95(6):2680–2688
Santonati A, Palermo A, Maddaloni E et al. (2015) PTH (1-34) for surgical hypoparathyroidism: a prospective open label investigation of efficacy and quality of life. J Clin Endocrinol Metab 100(9):3590–3597
Cusano NE, Rubin MR, McMahon DJ et al. (2013) Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab 98(1):137–144
Mannstadt M, Clarke BL, Vokes T et al. (2013) Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol 1(4):275–283
Rubin MR, Dempster DW, Sliney J Jr et al. (2011) PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res 26(11):2727–2736
Cusano NE, Rubin MR, McMahon DJ et al. (2013) The effect of PTH(1-84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab 98(6):2356–2361
Andrews EB, Gilsenan AW, Midkiff K et al. (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 27(12):2429–2437
Cipriani C, Irani D, Bilezikian JP (2012) Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res 27(12):2419–2428
Winer KK, Zhang B, Shrader JA et al. (2012) Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab 97(2):391–399
Winer KK, Fulton KA, Albert PS et al. (2014) Effects of Pump versus Twice-Daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism. J Pediatr 165(3):639
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflitto di interesse
Gli autori Serena Palmieri, Cristina Eller-Vainicher e Iacopo Chiodini dichiarano di non avere conflitti di interesse.
Consenso informato
Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.
Studi sugli animali
Gli autori di questo articolo non hanno eseguito studi sugli animali.
Additional information
Proposto da Salvatore Minisola.
Materiale elettronico supplementare
Rights and permissions
About this article
Cite this article
Palmieri, S., Eller-Vainicher, C. & Chiodini, I. Terapia dell’ipoparatiroidismo con paratormone. L'Endocrinologo 16, 245–252 (2015). https://doi.org/10.1007/s40619-015-0161-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40619-015-0161-y